Evidence map›Paper›PMID 42850729›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Sonogenetic Control of Engineered Probiotics for the Treatment of MASH by Modulating the Gut-Liver Axis.

Chunya Ji, Yan Fang, Shen Zhang, Weichen Xu, Wenyun Guo, Jing Chen, Mingrui Zhu, Congjian Wen, Siming Chen, Yuli Zhu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chunya Ji *Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-7664-0819
Yan Fang *Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China.
Shen Zhang *Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China.
Weichen XuDepartment of Medical Ultrasound, Center of Minimally Invasive Treatment for Tumor, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Wenyun GuoDepartment of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China.
Jing ChenDepartment of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China.
Mingrui ZhuDepartment of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China.
Congjian WenDepartment of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China.
Siming ChenSchool of Data Science, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-2690-3588
Yuli ZhuDepartment of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0009-0008-1584-8772
Huixiong XuDepartment of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-1977-0449
Haohao YinDepartment of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-5404-7336

Funding

China Postdoctoral Science Foundation 2023TQ0073Health Commission Health Sector Clinical Research Special Clinical Project 202340087National Natural Science Foundation of China 82430064National Nature Science Foundation of China 81927801,82302206,82102050Scientific Research and Development, Fund of Zhongshan Hospital of Fudan University 2022ZSQD07Shanghai Sailing Program 23YF1441600Suzhou Gusu Health Talents Program GSWS2023027
6 · The paper itself

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) currently lacks effective targeted therapeutics, while interleukin-22 (IL-22) as a potential treatment approach faces challenges in the clinical translation due to off-target risks associated with systemic delivery. To address this limitation, we developed an intelligent oral biologics platform centered on an engineered probiotic strain (Escherichia coli Nissle 1917) capable of producing therapeutic IL-22 in situ, encapsulated within an inulin hydrogel to resist gastric degradation. Critically, we integrated a sonogenetic control module that enables non-invasive, spatiotemporally precise activation of IL-22 expression in the gut via remote ultrasound stimulation. In MASH model, this targeted, on-demand IL-22 delivery effectively remodeled the gut microbiota and improved intestinal barrier function. This led to significantly reduced portal lipopolysaccharide (LPS) levels, which in turn decreased hepatic IL-6 production. Mechanistically, this strategy inhibited the pathological overactivation of the PI3K-AKT-mTOR signaling pathway, thereby markedly ameliorating hepatic steatosis, inflammation, and fibrosis. Notably, by confining IL-22 production to the gut, this strategy completely circumvented the off-target effects of conventional IL-22 therapy. We observed reversal of MASH-associated cognitive impairment, highlighting systemic benefits of restoring gut-liver axis homeostasis. This study establishes a transformative, multi-beneficial MASH therapy paradigm by modulating the gut-liver axis, offering a safe, effective, clinically translatable strategy.

Indexed as

engineered probioticsgut‐liver axisinterleukin‐22MASHsonogenetics

Identifiers

PMID42850729
PMCPMC13650197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.